Partnering opportunity

Serpin inhibitors for the treatment of prion and prion like diseases - License agreements and joint venture opportunity


A research group based in Italy has developed a new class of small molecules acting as SERPINA3 inhibitors, which are able to reduce prion protein (PrPSc) accumulation in prion-infected cell lines, thereby representing a new therapeutic treatment against prion and prion-like diseases. They are looking for licence agreements and joint venture agreements with pharma companies and/or financial agreements with investors.

Partner sought

Pharma Companies/Investors interested in acquiring and co-developing the technology.


To date, despite numerous active efforts, there are no drugs available for the cure of the neurodegenerative diseases collectively referred as prion and prion-like disorders. Symptomatic treatment is the only available option, including the administration to patients of antipsychotics, such as quetiapine and clonazepam, to treat myoclonus, and of selective serotonin re-uptake inhibitors (SSRIs) to treat depression. Indeed, through this invention, the technology transfer office of a research center based in the North of Italy and internationally renowned, is presenting a new class of small molecules. These small molecules are acting as SERPINA3 inhibitors, which are able to reduce PrPSc accumulation in prion-infected cell lines, thereby representing a new therapeutic treatment against prion and prion-like diseases. The development of specific inhibitors of SERPINA3 with an activity in the nanomolar range is expected. The characterization of structural models of the binding of the small molecules with the protein should allow the identification of novel inhibitors with improved potency. The research center is looking for licence agreements or joint ventures with industry (pharma companies) or financial agreements with investors interested in developing new drugs.

Advantages and innovations

So far there are no effective therapies for prion diseases. The proposed technology aims at developing novel molecules with improved efficacy on these diseases.

Development stage

Under development/lab tested

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted

Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company